Shield Therapeutics (STX) Hits New 12-Month Low at $108.00

Shield Therapeutics plc (LON:STX)’s share price reached a new 52-week low on Thursday . The stock traded as low as GBX 108 ($1.45) and last traded at GBX 115 ($1.55), with a volume of 4500 shares changing hands. The stock had previously closed at GBX 117.50 ($1.58).

STX has been the topic of several research reports. FinnCap restated a “buy” rating and issued a GBX 265 ($3.57) target price on shares of Shield Therapeutics in a research report on Tuesday, November 21st. Peel Hunt restated a “buy” rating and issued a GBX 220 ($2.96) target price on shares of Shield Therapeutics in a research report on Wednesday, November 8th. Finally, Liberum Capital reaffirmed a “buy” rating and issued a GBX 245 ($3.30) price target on shares of Shield Therapeutics in a report on Tuesday, October 10th.

ILLEGAL ACTIVITY WARNING: This story was reported by Stock Observer and is the sole property of of Stock Observer. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.thestockobserver.com/2017/12/07/shield-therapeutics-stx-hits-new-12-month-low-at-108-00.html.

About Shield Therapeutics

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company’s product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed.

Receive News & Ratings for Shield Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply